Glaukos (GKOS) Stock

The main figures for Glaukos (GKOS) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be useful to compare some important metrics with Wall Street predictions and the results from the same period last year.

The call began at 4:30 PM ET on November 4, 2024, for Glaukos Corporation's Q3 2024 earnings. Key company participants included Chris Lewis, Tom Burns, Joe Gilliam, and Alex Thurman. Various analysts from firms like Stifel, Wells Fargo, and JPMorgan also joined the call.

Glaukos (GKOS) reported a quarterly loss of $0.28 per share, which is better than the Zacks Consensus Estimate of a $0.52 loss. This is an improvement compared to a loss of $0.50 per share from the same period last year.

Glaukos (GKOS) has the right mix of two important factors that could lead to a strong earnings report soon. Be ready for the main expectations.

Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.

GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.

GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.